Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had […]
TSX News -
Mattr Commences Production at Two New Composite Technologies Facilities, on Time and on Budget
TORONTO, July 17, 2024 (GLOBE NEWSWIRE) — Mattr Corp. (“Mattr” or the “Company”) (TSX: MATR) announced today that it has […]
Lilium Reaffirms 2026 Target for First Customer Deliveries and Provides Additional Detail on Testing Program
First aircraft (Lilium Jet MSN 1) to be used exclusively for ground testing starting in a few weeks Second aircraft […]
Guardforce AI Expands Contracts with Two Major Retail Customers
Increases business footprint to nearly 20,000 retail stores across Asia Pacific New services include smart retail solutions to enhance store […]
Enovix to Release Second Quarter 2024 Financial Results on July 31, 2024
FREMONT, Calif., July 17, 2024 (GLOBE NEWSWIRE) — Enovix Corporation (“Enovix”) (Nasdaq: ENVX), a global high-performance battery company, today announced […]
Cellebrite Advances Plans to Transform and Elevate its Strategic Relationship with the U.S. Federal Government
TYSONS CORNER, Va. and PETAH TIKVA, Israel, July 17, 2024 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a leader in digital […]
Bread Financial™ Promotes Gender Equity with $1 Million Gift to the Women’s Sports Foundation®
COLUMBUS, Ohio, July 17, 2024 (GLOBE NEWSWIRE) — Bread Financial, a tech-forward financial services company that provides simple, personalized payment, […]
Gauzy’s Advanced Driver Assistance Systems (ADAS) Enhances Public Safety at the 2024 Paris Olympics With More Than 11 Million Expected Visitors
TEL AVIV, Israel, July 17, 2024 (GLOBE NEWSWIRE) — Gauzy Ltd. (Nasdaq: GAUZ) (“Gauzy” or the “Company”), a leading developer […]
Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board
MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) — Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage […]
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
SciSparc will receive additional payments and execution fees if certain milestones are met TEL AVIV, Israel, July 17, 2024 (GLOBE […]
